Clinical and demographic characteristics of patients with MF stratified by diagnosis (N = 95)
| Characteristic . | All patients (N = 95) . | PMF (n = 54) . | PPV-MF (n = 31) . | PET-MF (n = 10) . | P value . |
|---|---|---|---|---|---|
| Age (years) | 66 (40-84) | 54 (40-84) | 66 (52-80) | 72 (60-80) | .025 |
| Sex (female) | 42 (44) | 32 (59) | 17 (55) | 4 (40) | .526 |
| Hg (g/dL), mean (range) | 10.7 (7.2-16.9) | 11 (7.2-16.9) | 11 (8.7-14.5) | 10 (8.5-13.2) | .099 |
| WBC (109/L), mean (range) | 25 (2.5-159) | 24 (2.5-159) | 30 (2.9-100) | 12 (2.7-26.9) | .008 |
| Plt (109/L), mean (range) | 339 (13-969) | 295 (13-871) | 392 (102-835) | 416 (113-969) | .083 |
| PBBL (%), mean (range) | 0.96 (0-8.0) | .917 | |||
| PBBL ≥1% | 26 (27) | 13 (24) | 10 (32) | 3 (30) | .704 |
| Baseline spleen size (cm), mean (range) | 19.3 (3-35) | .027 | |||
| Transfusion dependence* | 23 (24) | 12 (22) | 7 (23) | 4 (40) | .468 |
| DIPSS Int-2 | 50 (57) | 30 (58) | 14 (54) | 6 (60) | .927 |
| Leukemic transformation | 7 (7.4) | 4 (7.4) | 2 (6.5) | 1 (10) | .933 |
| Cytogenetics | |||||
| Diploid | 54 (57) | 33 (61) | 13 (42) | 8 (80) | .221† |
| Abnormal | 38 (40) | 19 (35) | 17 (55) | 2 (20) | |
| IM | 3 (3.2) | 2 (3.7) | 1 (3.2) | 0 | |
| der(6)t(1;6)(q21-25;p21.3-23) | 5 (5.3) | 2 (3.7) | 3 (9.7) | 0 | |
| del13(q12-14;q14-22) | 9 (9.5) | 5 (5.3) | 4 (13) | 0 | |
| del20(q11.21;q13.3) | 12 (13) | 6 (6.3) | 5 (16) | 1 (10) | |
| Average dose intensity | .549 | ||||
| ≤10 mg BID | 20 (21) | 10 (18) | 6 (19) | 4 (40) | |
| >10 to ≤20 mg BID | 42 (44) | 23 (43) | 15 (48) | 4 (40) | |
| >20 mg BID | 33 (35) | 21 (39) | 10 (32) | 2 (20) | |
| G3/4 hematologic toxicities | |||||
| G3/4 anemia/thrombocytopenia | 70 (74) | 39 (72) | 22 (71) | 9 (90) | .461 |
| No G3/4 anemia/thrombocytopenia | 25 (26) | 15 (28) | 9 (30) | 1 (10) | .205 |
| G3/4 anemia | 34 (36) | 16 (30) | 13 (43) | 5 (50) | |
| G3/4 thrombocytopenia | 18 (19) | 12 (22) | 6 (20) | 0 | |
| G3/4 anemia and thrombocytopenia | 18 (19) | 11 (20) | 3 (10) | 4 (40) | |
| IWG spleen response (N = 88) | 63 (72) | 33 (66) | 22 (79) | 8 (80) | .409 |
| IWG SR duration, mean (weeks) (N = 63) | 34.7 (2.8-74.2) | 29.8 (2.8-68.5) | 39.8 (4.8-74.2) | 41 (13.5-58.9) | .309 |
| Patients still on study (N = 20) | 20 (21) | 7 (13) | 12 (39) | 1 (10) | .013 |
| TTD, mean (weeks) | 177 (7-387) | 151 (9-369) | 213 (7-387) | 206 (60-328) | .052 |
| Overall survival, mean (weeks) | 207 (7-387) | 194 (43-372) | 243 (7-387) | 246 (60-336) | .058 |
| Characteristic . | All patients (N = 95) . | PMF (n = 54) . | PPV-MF (n = 31) . | PET-MF (n = 10) . | P value . |
|---|---|---|---|---|---|
| Age (years) | 66 (40-84) | 54 (40-84) | 66 (52-80) | 72 (60-80) | .025 |
| Sex (female) | 42 (44) | 32 (59) | 17 (55) | 4 (40) | .526 |
| Hg (g/dL), mean (range) | 10.7 (7.2-16.9) | 11 (7.2-16.9) | 11 (8.7-14.5) | 10 (8.5-13.2) | .099 |
| WBC (109/L), mean (range) | 25 (2.5-159) | 24 (2.5-159) | 30 (2.9-100) | 12 (2.7-26.9) | .008 |
| Plt (109/L), mean (range) | 339 (13-969) | 295 (13-871) | 392 (102-835) | 416 (113-969) | .083 |
| PBBL (%), mean (range) | 0.96 (0-8.0) | .917 | |||
| PBBL ≥1% | 26 (27) | 13 (24) | 10 (32) | 3 (30) | .704 |
| Baseline spleen size (cm), mean (range) | 19.3 (3-35) | .027 | |||
| Transfusion dependence* | 23 (24) | 12 (22) | 7 (23) | 4 (40) | .468 |
| DIPSS Int-2 | 50 (57) | 30 (58) | 14 (54) | 6 (60) | .927 |
| Leukemic transformation | 7 (7.4) | 4 (7.4) | 2 (6.5) | 1 (10) | .933 |
| Cytogenetics | |||||
| Diploid | 54 (57) | 33 (61) | 13 (42) | 8 (80) | .221† |
| Abnormal | 38 (40) | 19 (35) | 17 (55) | 2 (20) | |
| IM | 3 (3.2) | 2 (3.7) | 1 (3.2) | 0 | |
| der(6)t(1;6)(q21-25;p21.3-23) | 5 (5.3) | 2 (3.7) | 3 (9.7) | 0 | |
| del13(q12-14;q14-22) | 9 (9.5) | 5 (5.3) | 4 (13) | 0 | |
| del20(q11.21;q13.3) | 12 (13) | 6 (6.3) | 5 (16) | 1 (10) | |
| Average dose intensity | .549 | ||||
| ≤10 mg BID | 20 (21) | 10 (18) | 6 (19) | 4 (40) | |
| >10 to ≤20 mg BID | 42 (44) | 23 (43) | 15 (48) | 4 (40) | |
| >20 mg BID | 33 (35) | 21 (39) | 10 (32) | 2 (20) | |
| G3/4 hematologic toxicities | |||||
| G3/4 anemia/thrombocytopenia | 70 (74) | 39 (72) | 22 (71) | 9 (90) | .461 |
| No G3/4 anemia/thrombocytopenia | 25 (26) | 15 (28) | 9 (30) | 1 (10) | .205 |
| G3/4 anemia | 34 (36) | 16 (30) | 13 (43) | 5 (50) | |
| G3/4 thrombocytopenia | 18 (19) | 12 (22) | 6 (20) | 0 | |
| G3/4 anemia and thrombocytopenia | 18 (19) | 11 (20) | 3 (10) | 4 (40) | |
| IWG spleen response (N = 88) | 63 (72) | 33 (66) | 22 (79) | 8 (80) | .409 |
| IWG SR duration, mean (weeks) (N = 63) | 34.7 (2.8-74.2) | 29.8 (2.8-68.5) | 39.8 (4.8-74.2) | 41 (13.5-58.9) | .309 |
| Patients still on study (N = 20) | 20 (21) | 7 (13) | 12 (39) | 1 (10) | .013 |
| TTD, mean (weeks) | 177 (7-387) | 151 (9-369) | 213 (7-387) | 206 (60-328) | .052 |
| Overall survival, mean (weeks) | 207 (7-387) | 194 (43-372) | 243 (7-387) | 246 (60-336) | .058 |
Hg, hemoglobin; IM, not measurable; IWG, international working group; PBBL, peripheral blood blasts; PET-MF, postessential thrombocythemia myelofibrosis; Plt, platelets; PMF, primary myelofibrosis; PPV-MF, postpolycythemia vera myelofibrosis; SR, spleen response; WBC, white blood cell.
Transfusion dependence was defined as patients who required transfusions at the time they started on ruxolitinib.
Comparison is between diploid, abnormal, and IM.